Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101

Jade Biosciences, Inc.

Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.
Patheon MSA covers cGMP manufacturing for JADE101 and future programs; initial 5-year term with auto-renewal; non-cancellable fees per project.
Dahms previously CFO of IDRx (sold to GSK), Theseus (sold to Concentra), and Selecta; brings 15 years biotech and investment banking experience.
Company advancing JADE101 into clinic this year for IgA nephropathy; recent Nasdaq listing and private financing provide momentum.

item 1.01item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.